You have 9 free searches left this month | for more free features.

duvelisib

Showing 1 - 25 of 29

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

COVID-19 Trial in Saint Louis (Duvelisib, Peripheral blood draw, Placebo)

Completed
  • COVID-19
  • Duvelisib
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Aug 9, 2022

Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma Trial in Tampa (CC-486, Duvelisib)

Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Aug 15, 2022

Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia Trial in Saint Louis (Duvelisib)

Recruiting
  • Non-hodgkin Lymphoma
  • Acute Lymphocytic Leukemia
  • Duvelisib
  • Saint Louis, Missouri
    Washington University School of Medicine
Jun 30, 2022

Unresectable Melanoma Trial in Pittsburgh (Nivolumab, Duvelisib)

Recruiting
  • Unresectable Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Apr 19, 2022

COVID-19 Trial in Atlanta (Duvelisib, Placebo)

Completed
  • COVID-19
  • Duvelisib
  • Placebo
  • Atlanta, Georgia
  • +2 more
Jun 10, 2022

Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)

Terminated
  • Small Lymphocytic Leukemia (SLL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 15, 2022

Advanced Solid Tumors Trial (Duvelisib, SG001)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Aug 18, 2022

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Feb 7, 2022

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Chronic Lymphocytic Leukemia, Richter Syndrome Trial in United States (Duvelisib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Miami, Florida
  • +6 more
Jul 5, 2022

T-cell Lymphomas, NK-Cell Lymphomas Trial in United States (Ruxolitinib, Duvelisib)

Recruiting
  • T-cell Lymphomas
  • NK-Cell Lymphomas
  • Miami, Florida
  • +8 more
Aug 1, 2022

Hematologic Malignancy Trial in Italy, United States (Duvelisib)

Completed
  • Hematologic Malignancy
  • Duvelisib
  • Denver, Colorado
  • +4 more
Mar 15, 2021

Follicular Lymphoma Trial in Worldwide (Duvelisib, Placebo, Rituximab)

Terminated
  • Follicular Lymphoma
  • Duvelisib
  • +2 more
  • Frankston, Victoria, Australia
  • +4 more
Mar 15, 2021

Lymphoma Trial in Miami (Duvelisib, Rituximab, R-CHOP)

Withdrawn
  • Lymphoma
  • Duvelisib
  • +3 more
  • Miami, Florida
    (unnamed)
Mar 15, 2021

Head and Neck Squamous Cell Carcinoma Trial in Pittsburgh (duvelisib, pembrolizumab)

Suspended
  • Head and Neck Squamous Cell Carcinoma
  • duvelisib
  • pembrolizumab
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 15, 2021

Follicular Lymphoma Trial in Shanghai (Duvelisib)

Unknown status
  • Follicular Lymphoma
  • Duvelisib
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
Jan 10, 2021

Peripheral T-cell Lymphoma Trial in Worldwide (Duvelisib)

Active, not recruiting
  • Peripheral T-cell Lymphoma
  • Duvelisib
  • Duarte, California
  • +27 more
May 3, 2022

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV

Recruiting
  • Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
  • +2 more
  • Duvelisib
  • +2 more
  • Phoenix, Arizona
  • +11 more
Aug 6, 2022

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in United States (Duvelisib, Placebo,

Withdrawn
  • Indolent Non-Hodgkin's Lymphoma
  • +3 more
  • Duvelisib
  • +3 more
  • Plainville, Connecticut
  • +6 more
Mar 15, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Duvelisib)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Duvelisib
  • Tempe, Arizona
  • +7 more
Mar 15, 2021

CD20+ Follicular Lymphoma Trial in Worldwide (Duvelisib, Rituximab, Obinutuzumab)

Terminated
  • CD20+ Follicular Lymphoma
  • Duvelisib
  • +2 more
  • Los Angeles, California
  • +20 more
Mar 15, 2021

Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma Trial in United States

Recruiting
  • Angioimmunoblastic T-cell Lymphoma
  • +6 more
  • Los Angeles, California
  • +20 more
Aug 2, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (Duvelisib, Ofatumumab)

Completed
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • La Jolla, California
  • +91 more
Dec 14, 2021

Indolent Non-Hodgkin Lymphoma Trial in Worldwide (Duvelisib)

Active, not recruiting
  • Indolent Non-Hodgkin Lymphoma
  • Duvelisib
  • Los Angeles, California
  • +68 more
Mar 15, 2021